You are here: Industry Insights > Itolizumab

News List

Biocon Q1FY22 revenue at Rs 1,808 crores, up six per cent expresspharma
July 23, 2021
Biosimilars up 10 per cent at Rs 758 crores and research services up 41 per cent at Rs 595 crores.
SEC asks Biocon to submit safety, mortality data for Itolizumab expresspharma
December 03, 2020
The company claims that approximately 2000 COVID-19 patients used the drug under the emergency use authorisation.
Biocon’s itolizumab fails to be part of Covid-19 management protocols pharmaceutical-technology
July 28, 2020
The National Task Force for Covid-19 in India has denied the inclusion of Biocon’s itolizumab in its clinical management protocols for the disease.
Biocon presents key Insights into clinical study that enabled DCGI approval of Itolizumab expresspharma
July 15, 2020
A multi-centric, open label, two-arm randomized pivotal clinical trial was conducted in 30 eligible patients at four hospitals across Mumbai and New Delhi.
Biocon to launch drug for COVID-19 patients; priced at Rs 8,000 per vial expresspharma
July 14, 2020
Itolizumab is the first novel biologic therapy to be approved anywhere in the world for treating patients with moderate to severe COVID-19 complications, Biocon had earlier said in a regulatory filing.
Biocon’s drug Itolizumab gets approval to treat Covid-19 pharmaceutical-technology
July 14, 2020
Biopharmaceuticals company Biocon has secured approval from the Drugs Controller General of India (DCGI) for its plaque psoriasis drug Itolizumab (ALZUMAb) for emergency use in Covid-19 patients.
DCGI approves Itolizumab for restricted emergency use in COVID-19 treatment expresspharma
July 13, 2020
The approval was given after its clinical trials on COVID-19 patients in India was found satisfactory by an expert committee, informed the drug regulator.